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doi:10.1016/j.jfma.2011.01.006Background/Purpose: To describe a single center’s experience with pediatric patients
receiving extracorporeal membrane oxygenation (ECMO) for respiratory failure due to acute
respiratory distress syndrome (ARDS) associated with pneumonia and to investigate the factors
associated with mortality.
Methods: Retrospective chart review of all pediatric patients receiving ECMO for severe ARDS
associated with pneumonia and sepsis from December 2001 to October 2009 in the pediatric
intensive care unit (ICU) and cardiovascular surgery ICU at a tertiary medical center, to inves-
tigate the factors associated with mortality.
Results: Twelve patients had pneumonia and sepsis with progression to ARDS. The duration of
intubation prior to ECMO was 19.92  10.40 hours. The duration of ECMO support was
241.08 194.93 hours. The range of PaO2/FiO2 was 42e69.9, alveolarearterial oxygen gradient
(AaDO2) 602e645, and oxygenation index (OI) 27.4e68. The pre-ECMO intubation duration in
the initial venoarterial ECMO group was significantly different from the venovenous ECMO
group (9.4 10.93 vs. 151.25 152.16 hours). The overall survival to lung recovery rate was
66.7% (8/12) and survival to discharge rate 58.3%. The survival rate to lung recovery improved
from 20% (between 2001 and 2003) to 100% (after 2004). Between the survival and nonsurvival
groups, only ICU days and total intubated days were significantly longer in survivors. Although
without statistical significance, the nonsurvivors tended to have lower white blood cell counts,
higher C-reactive protein (CRP), and longer pre-ECMO intubation time. Seven of the 12 patientsof Pediatrics, Mackay Memorial Hospital, 92, Section 2, Chung-Shan North Road, Taipei 104, Taiwan,
h.org.tw (M.-R. Chen).
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148 C.-C. Peng et al.had bacterial pneumonia, higher CRP and creatinine values, and a lower hospital survival rate
compared to the nonbacterial group (42.8% vs. 80%).
Conclusion: Application of ECMO in pediatric patients with severe ARDS seems effective in
improving survival, even under the conditions of pneumonia with septic shock.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Acute respiratory distress syndrome (ARDS) refers to
a clinical syndrome characterized by bilateral infiltrates on
chest radiography, absence of left atrial hypertension
(pulmonary artery occlusion pressure <18 mmHg), and
impaired oxygenation. PaO2/FiO2 < 300 is defined as acute
lung injury (ALI); however, in ARDS, the PaO2/FiO2 is <200.
1
It is a condition associated with significant morbidity and
mortality in children. Zimmerman et al2 summarized the
reported pediatric ALI mortality rates from published
investigations, which ranged from 19% to 90%, with lower
mortality rates in more recent studies. Their study reported
the first population-based data for pediatric ALI, with an
incidence of 12.8 cases per 100,000 person-years and
a hospital mortality rate of 18%.
Therapies including lung-protective ventilation strate-
gies, inhaled nitric oxide, surfactant therapy, and high-
frequency oscillation ventilation have been introduced over
the last decade.3 Extracorporeal membrane oxygenation
(ECMO) has been used to treat acute hypoxic respiratory
failure since the 1970s.4 It is an accepted therapy for
neonatal pulmonary failure, but its use in older children has
been controversial. The Cochrane Database of Systematic
Reviews concluded that using ECMO in mature infants with
severe but potentially reversible respiratory failure would
result in significantly improved survival without an
increased risk of severe disability among the survivors.5 In
a nonrandomized study in a pediatric age group, Frenckner
and Radell6 reported lower mortality in ECMO-treated
patients. Green et al7 reported on the Pediatric Study
Group, which set out to identify the role of ECMO in chil-
dren with severe respiratory failure. They compared an
ECMO group with a non-ECMO group, based on the Pediatric
Risk of Mortality score, and the ECMO cohort was found to
have a better survival.
The etiology of ARDS is heterogeneous. Pneumonia and
sepsis are the most common risk factors.2,8,9 The aim of this
report is to present our clinical experience of ECMO for
ARDS associated with pneumonia unresponsive to conven-
tional treatment in children.Materials and methods
In the single tertiary pediatric intensive care unit (ICU) at
Mackay Memorial Hospital, a medical center in Taiwan,
medical records from December 2001 to October 2009
were reviewed retrospectively. Twelve patients with ARDS
who failed maximal ventilator support and who were
treated with ECMO were enrolled, with a mean age of 4.6
years (range 1.9e13.3 years) and a mean body weight of19 kg (range 11.5e40 kg). The American European
Consensus Conference ALI and ARDS criteria were used to
diagnose ARDS. ARDS was diagnosed when the patient
presented with severe hypoxemia (PaO2/FiO2 is <200),
chest radiography showed bilateral infiltration, and left
atrial pressure was normal on two-dimensional and Doppler
echocardiographic evaluation of transmitral and pulmo-
nary venous flow. The informed consent was obtained from
parents.
Pre-ECMO respiratory care
Prior to ECMO, the setting of conventional ventilation
(Servo 300 or Servo i) was set as pressure controlled, assist/
control mode with a peak inspiratory pressure (PIP)
<30e35 cmH2O, and positive-end expiratory pressure
(PEEP) between 7 and 10 cmH2O to keep SpaO2 >88%. High-
frequency oscillatory ventilation (HFOV), SensorMedics
3100A, has been used in our ICU since 2002. Ventilation was
shifted from conventional to HFOV when SPO2 could not be
kept over 88% and HFOV could achieve higher SPO2. Inhaled
nitric oxide (NO) was given to select patients with severe
hypoxemia.
Criteria for ECMO setup
ECMO was initiated because of failed maximal medical or
ventilatory therapy, and because mortality was predicted by
the entire team of physicians if ECMO was not set up. The
criteria included high ventilator setting (PIP >35 cmH2O,
PEEP>10 cmH2Owith FiO2 1.0), severe hypoxemia [alveolare
arterial oxygen gradient (AaDO2) > 600 or oxygenation index
(OI) > 40], or severe shock with unstable hemodynamic
status.
ECMO method and patient care
The ECMO pump used was a centrifugal pump (Medtronic
Inc., Anaheim, CA, USA). In the four venovenous (VV)-ECMO
patients, the femoral vein and right internal jugular vein
were cannulated. Hollow-fiber membrane oxygenators
were used for gas exchange. On the other hand, in the eight
venoarterial (VA)-ECMO patients, the right carotid artery
and right internal jugular vein were cannulated. Four of
them were shifted to VV mode after cardiac function
recovery. The cut-down method was used to ensure proper
vascular cannulation. The size of the cannula (Medtronic
Inc.) was chosen according to the body weight of the
patient. Prior to cannulation, unfractionated heparin 100
units/kg was given intravenously. During ECMO therapy,
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clotting time between 160 and 200 seconds. Inotropic
agents were tapered according to the hemodynamics. The
ventilation setting during ECMO was reduced to an
acceptably low level (PIP < 30 cmH2O, PEEP 5e7 cmH2O,
FiO2 < 0.4, rate 15e25/min). Blood component trans-
fusion, total parenteral nutrition, and antibiotics were used
according to the clinical condition. When removing ECMO,
all vessels in the cannulation site were repaired with pro-
lene sutures.
Data collection and statistical analysis
The demographic characteristics, chronic illness, clinical
presentation, the mode and duration of ECMO and pre-
ECMO parameters, and outcomes were analyzed. The pre-
ECMO parameters, AaDO2, OI, and inotropic equivalent,
were calculated as follows:
AaDO2Z ð713  FiO2ePaCO2=0:8ÞePaO2
OIZ ðMAP  FiO2  100Þ=PaO2
IEðinotropicequivalentÞZ dopamine þ dobutamine þ 100
 epinephrine þ 100  norepinephrine þ 100
 isoproterenol þ 15  milrinone
Other parameters included white blood cell (WBC),
hemoglobin, C-reactive protein (CRP), creatinine, arterial
blood gas, and ventilation setting: PIP, PEEP, and mean
airway pressure (MAP).
The outcome measures were survival to lung recovery,
survival to hospital discharge, total intubation days, hospital
days, and complications. Lung recovery was defined as
successful weaning and decannulation from ECMO.Table 1 Demographics of ARDS children treated with ECMO.
No. Year Sex Age
(years)
BW
(kg)
Pathogen Pre-existent
diseases
1 2001 F 2.6 14 S pneumoniae
2 2002 M 5.5 24 S pneumoniae
3 2002 F 2.1 11.5 S pneumoniae
4 2002 M 4.3 14.6 S pneumoniae
5 2003 M 13.3 40 S aureus
6 2004 F 3.3 20 Unknown PradereWill
syndrome
7 2004 F 4.3 17 S pneumoniae
8 2007 F 4.2 16 S pneumoniae
9 2008 M 3.9 13.8 M pneumoniae
10 2009 M 3.4 14 M pneumoniae Asthma
11 2009 M 7 37 Influenza Seizure diso
12 2009 M 1.9 10.4 Cytomegalovirus AMLb
AMLZ acute myeloid leukemia; ARDSZ acute respiratory distress s
membrane oxygenation; FZ female; MZmale; S*Z survived to
VVZ venovenous.
a Total hospitalization days.
b M7 after chemotherapy with remission.All values are reported as mean values with standard
deviation. The ManneWhitney rank sum test was used to
compare continuous variables between subgroups. Student
t tests were used for categorical variables. Statistical
significance was demonstrated at p< 0.05.Results
Demographic characteristics of the patients, pathogens of
pneumonia, pre-existing diseases, duration of pre-ECMO
intubation, mode and duration of ECMO, and outcomes are
listed in Table 1. Among the 12 patients, initial symptoms
included fever, cough, and dyspnea. The average duration
between the onset of symptoms and the development of
ARDS was 6 days (0e10 days). All chest X-ray pictures
revealed a white-out picture prior to ECMO. Six patients
had pleural effusion, and bilateral chest tubes were inser-
ted in three patients. The pathogens of pneumonia were
diagnosed as Streptococcus pneumoniae in six patients,
Mycoplasma pneumoniae in two patients, and Staphylo-
coccus aureus, influenza, and cytomegalovirus in one
patient each. One patient had no definitively identified
pathogen, but viral infection was highly suspected. All 12
patients had sepsis. T-antigen was positive in four of six
patients with pneumococcal pneumonia. Three developed
hemolytic uremic syndrome. Acute renal failure was found
in six patients, and three of them received peritoneal
dialysis prior to ECMO rescue therapy. Two patients
received HFOV and two patients received inhaled NO
therapy prior to ECMO. The duration of intubation prior to
ECMO was 19.92 10.40 hours (range 2e336 hours). The
duration of ECMO support was 241.08 194.93 hours (range
24e689 hours). In eight patients, VA ECMO was indicated for
intractable shock and respiratory failure; four received VV
ECMO for respiratory failure only. VA ECMO was changed to
VV ECMO when the cardiac function had recovered in four
of the eight patients.Pre-ECMO
intubation (h)
ECMO
duration (h)
ECMO
mode
Outcome (da)
216 192 VV D (19)
9 684 VA/VV S* (57)
5 58 VA D (5)
336 240 VV D (26)
19 24 VA D (3)
i 30 47 VA S* (37)
3 108 VA S* (29)
3 140 VA/VV S* (23)
24 239 VA/VV S* (88)
2 435 VA/VV S* (67)
rder 29 417 VV S* (49)
24 309 VV S# D (77)
yndrome; BWZ body weight; DZ died; ECMOZ extracorporeal
discharge; S#Z survived to lung recovery; VAZ venoarterial;
150 C.-C. Peng et al.Table 2 lists the pre-ECMO parameters and comparisons
between the survival and nonsurvival groups, and between
the bacterial and nonbacterial groups. Overall, lung injury
was very severe in our series. The range of PaO2/FiO2 was
42e69.9, AaDO2 602e645, and OI 27.4e68; 67% of the
patients had severe septic shock with higher IE and rapid
progression, and received VA ECMO initially. The IE in the
initial VA-ECMO group was 163.75 165.10 (range 40e440),
which was significantly different from that in the VV-ECMO
group (mean 10 8.16). The pre-ECMO intubation duration
was 9.4 10.93 hours (range 2e30 hours) in the initial VA-
ECMO group, which was significantly different from that
in the VV-ECMO group (151.25 152.16 hours; range
24e336 hours).
Between the survival andnonsurvival groups, only ICUdays
were significantly longer in survivors, although the survival
group had a trend of higher WBC count, lower CPR, shorter
pre-ECMO intubation period, and longer ECMO duration.
Between the bacterial and nonbacterial groups, the bacterial
group had significantly higher serum levels of CPR and
creatinine. There were no significant differences between
the survival and nonsurvival groups, and between the
bacterial and nonbacterial groups with respect to demo-
graphics, pre-ECMO setting, blood gas data, severity of lung
injury, left ventricular function, and inotropic equivalent.Table 2 Comparison of pre-ECMO parameters and clinical cour
Overall (12) Survived# (8)
Age (y) 4.65 3.07 4.19 1.53
Weight (kg) 19.36 9.67 19.03 8.36
Pre-ECMO ventilation
Duration (h) 58.3 105.36 15.5 12.38
PIP (cmH2O) 36.42 8.33 36.88 9.64
MAP (cmH2O) 20.63 4.87 20.94 5.95
PEEP (cmH2O) 8.58 2.57 8.5 2.07
Pre-ECMO arterial blood gas (ABG)
pH 7.304 0.137 7.33 0.1
PaO2 50.15 12.80 51.2 15.16
PaCO2 38.45 11.18 38.83 9.83
HCO2 18.8 5.66 20.31 5.78
PaO2/FiO2 63.00 12.31 54.19 14.54
AaDO2 623.30 18.65 620.68 18.82
OI 41.58 13.37 44.73 14.25
Pre-ECMO laboratory values
Hemoglobulin (mg/dL) 10.98 2.26 10.75 1.96
WBC count (/mL) 5345 5360.21 6742.5 1418.23
CRP (mg/dL) 22.76 13.46 18.77 6.43
Creatinine (mg/dL) 0.98 0.75 1.01 0.87
Pre-ECMO left ventricular
ejection fraction (LVEF)
60.83 19.27 66.71 8.53
Pre-ECMO IE 112.5 151.96 116.25 159.55
ECMO duration (h) 241.08 194.93 297.38 210.32
Total intubation days 19.92 10.40 23.75 8.43*
Total ICU days 30.17 21.68 39 20.62*
*ManneWhitney rank sum test, p< 0.05.
AaDO2Z alveolarearterial oxygen gradient; CRPZ C-reactive protein
care unit; IEZ inotropic equivalent; MAPZmean airway pressure
PIPZ peak inspiratory pressure; Survived#Z survived to lung recoveThe overall survival to lung recovery rate was 66.7% (8/
12) and survival to discharge rate 58.3% (Table 3). The
survival to lung recovery rate was 20% between 2001 and
2003, and then improved to 100% after 2004. Since there
were no differences between the ECMO technique and the
protocol, we believe that the improvement is likely due to
an increase in experience and operator skill. One patient
(Patient 12) with leukemia survived until lung recovery, but
died of hepatic failure and sepsis 2 months later. Four
patients died soon after removal of ECMO. The cause of
death in Patients 3 and 5 was hypoxic encephalopathy due
to unstable hemodynamic condition prior to VA-ECMO
setup. Patient 4 died of intracranial hemorrhage 10 days
after initiation of ECMO. In this case, the side effect of
systemic anticoagulation with heparin was considered. In
case of Patient 1, the cause of death was deterioration of
pulmonary function with persistent pneumothorax, despite
VV ECMO being used in that patient.
Complications associated with ECMO included central
nervous system lesions in three patients: one with a focal
ischemic infarction of the left basal ganglia who survived,
one who died of intracranial hemorrhage with diabetes
insipidus, and one who died of hypoxic-ischemia encepha-
lopathy with brain death. Another two had embolization
of the toes, which was resolved with prostaglandin E1se by subgroup.
Non-survived (4) Bacterial (7) Nonbacterial (5)
5.58 5.24 5.19 3.76 3.9 1.89
20.03 13.39 19.58 9.81 19.04 10.62
144 160.2 84.43 135.49 21.8 11.41
35.5 5.97 33.57 5.29 40.4 10.71
20 1.83 20.79 4.88 20.4 5.41
8.75 3.77 8.71 3.15 8.4 1.82
7.25 0.20 7.244 0.153 7.388 0.043
48.05 7.47 53.9 14.7 44.9 9.71
37.7 15.23 37.19 14.86 40.22 2.46
15.78 4.62 15.6 5.20 23.28 2.14
50.65 7.22 53.23 14.08 52.7 10.95
628.53 19.86 620.73 20.88 626.88 16.59
35.28 10.08 40.01 14.39 43.76 13.05
11.42 3.04 10.61 2.51 11.48 2.00
2550 1209.67 3358.57 2185.25 8126 7434.8
30.74 4.77 32.10 7.50* 9.69 6.93*
0.6 0.69 1.33 0.85* 0.48 0.26*
49.08 30.24 53.63 22.18 70.92 8.06
105 158.64 170 181.01 32 21.68
128.50 103.85 206.57 223.17 289.4 157.45
12.25 10.63* 14.43 10.00 27.6 4.56
12.5 10.38* 18.29 15.24 46.8 18.75
; ECMOZ extracorporeal membrane oxygenation; ICUZ intensive
; OIZ oxygen index; PEEPZ positive end expiratory pressure;
ry; WBCZwhite blood cell.
Table 3 Survival rate in ARDS children treated with ECMO.
Variable Survived to
lung recovery
Survived
to discharge
Overall 66.7% (8/12) 58.3% (7/12)
Years
2001e2003 20% (1/5) 20% (1/5)
2004e2009 100% (7/7) 85.7% (6/7)
Etiology
Bacterial pneumonia 42.9% (3/7) 42.9% (3/7)
Nonbacterial pneumonia 100% (5/5) 80% (4/5)
ECMO mode
Initial VV mode 50% (2/4) 25% (1/4)
Initial VA mode 75% (6/8) 75% (6/8)
ARDSZ acute respiratory distress syndrome; ECMOZ ex-
tracorporeal membrane oxygenation; FZ female; VAZ ve-
noarterial; VVZ venovenous.
ECMO for ARDS in children 151infusion; one had hemolysis and jaundice; and all 12 patients
had anemia and thrombocytopenia. Most survivors (6/7) had
functionally normal lives, including the patient with the
focal ischemic infarction of the left basal ganglia. One
(Patient 9) had severe hypoxic ischemic encephalopathy due
to bilateral pneumothorax with CPR after removal of ECMO.
Discussion
The overall hospital survival rate of our series was 58.3%
(survival to lung recovery rate 66.7%), and increased from
20% prior to 2003 to 85.7% after 2004 (survival to lung
recovery rate reached 100%)da favorable outcome
compared to the published survival rates of between 46%
and 77% for ECMO-treated children with acute respiratory
failure.10e18 Although lack of randomized trials, ECMO for
ARDS continues to be considered in any child with acute,
severe, reversible respiratory failure in spite of its high
cost. Vats’ retrospective review of the hospital charges
associated with the use of ECMO concluded that ECMO for
the pediatric patient is done even at a considerable cost,
because ECMO affects survival favorably and compares
favorably when considering cost/life-year calculations.19
In our series, all the patients with severe ARDS treated
with ECMO had diagnoses of pneumonia with sepsis. Sepsis
with septic shock seemed not to be a poor prognostic
factor. Even in patients with unstable hemodynamics
receiving higher doses of inotropic agents, the hospital
survival rate was as high as 75% (in our VA-ECMO group).
Meyer and Jessen20 also demonstrated that older children
frequently undergo ECMO for severe bacterial, viral, or
aspiration pneumonia and many have coexisting systemic
sepsis. However, systemic sepsis does not independently
influence survival in pediatric ECMO. Pathan et al17 under-
took a retrospective study to analyze predictors of outcome
and inclusion and exclusion criteria in 124 children, and
concluded that severity of pulmonary dysfunction and
shock were key predictors of outcome and should remain
important determinants of referral for ECMO.
To date, no clear inclusioneexclusion criteria have been
published for pediatric respiratory ECMO. For neonatalrespiratory ECMO, inclusion criteria were published in
1996.21 Most centers provide ECMO to non-neonatal
patients with severe respiratory failure when the maximal
ventilator and medical managements have failed or when
a high risk of mortality is predicted.10e13,16e18,22e24 The
detailed indicators or timing is difficult to define, and the
criteria vary from center to center, even in the report by
Extracorporeal Life Support Organization (ELSO).16 OI,
PaO2/FiO2, and AaDO2 are often used as inclusion criteria to
initiate respiratory ECMO.14,15,19 Similar to Wagner’s
report, we did not find a correlation between pre-operative
risk factors, including pH, pre-ECMO bloog gas, OI, PaO2/
FiO2, or AaDO2, and outcome in ECMO.
25 In neonatal pop-
ulations, OI exceeding 40 with a mortality rate exceeding
80% is the most widely accepted predictor of mortality and
used criteria for ECMO. Several studies have reported that
OI predicts outcome in children with acute hypoxemic
respiratory failure.7,17,26 Trachsel et al26 stated that peak OI
measured at any time point and Pediatric Risk of Mortality, or
PRISM, score within the first 12 hours of mechanical venti-
lation were independent predictors of mortality. However,
no clear-cut threshold of OI was identified that could predict
mortality accurately.26 In contrast to ALI/ARDS in adults,
initial severity of arterial hypoxemia (as measured by PaO2/
FiO2) in children correlates well with mortality.
9 Lew-
andowski27 reported that in severe ARDS, PaO2/FiO2 may be
<75 mmHg and the mortality risk may exceed 80%d a point
when ECMO is considered. Tamburro et al28 demonstrated
that conventional treatment can be considered to have
failed when AaDO2 exceeds 450 mmHg for over 24 hours, this
level predicting death most accurately. In our experience,
children with ARDS associated with pneumonia frequently
have sepsis as well. They have not only a rapidly progressive
hypoxia, but also a rapid deterioration in hemodynamic
function. Given these reasons, using the index of lung injury
or severity of acute respiratory failure alone as a criterion for
initiation of ECMO is not suitable. When mortality is foreseen
by the entire team and when medical therapy has already
reached its limits, it is time to set up ECMO.
The survival rate was lower in the bacterial pneumonia
group (42.9% vs. 80%) in our patients, similar to previous
reports. The published survival rate of ECMO-treated
bacterial pneumonia is 40e89%, and viral pneumonia
48e100%.11,13e18,23,29 Pneumococcal pneumonia remains an
important cause of mortality and morbidity in children. In
our series, six patients had fulminant community-acquired
pneumococcal pneumonia with a survival rate of 50%.
In our series, there was no difference in pre-ECMO
parameters between survivors and nonsurvivors. However,
patients with bacterial pneumonia had significantly higher
CRP, creatinine, and a lower survival rate. In 2008, Wagner
et al25 analyzed 26 preoperative risk factors of mortality in
72 patients with respiratory failure treated with ECMO, and
found that only preoperative serum creatinine levels
correlated with survival.25 Swaniker et al14 reviewed 128
pediatric patients with respiratory failure to determine the
variables predictive of outcome. They found that pH was
the only pre-ECMO variable significantly associated with
outcome when analyzed by multivariate logistic regression.
They compared survivor and nonsurvivors and found that
the variables significantly associated with decreased
survival were creatinine >3.0, the need for inotropes,
152 C.-C. Peng et al.failure to return the patient to dry weight, and lung
compliance that did not improve significantly.
VV ECMO decreases the risk of arterial embolization and
avoids carotid artery ligation.30 Two patients received VA
ECMO initially and developed embolization of the toes. This
was resolved after PGE1 infusion and shifted to VV mode
later. The survival rate was higher in VA-ECMO-treated
patients; the survival rate was not different for the two
groups (55.8% for VA vs. 60.1% for VV) in Zahraa et al’s31
report but higher in the VV-ECMO group (81% vs. 64%) in
Pettignano et al’s15 study.
Based on our results, we conclude that ECMO may
provide a chance of survival for children with severe ARDS
who are not responding to conventional treatment, even
under the conditions of pneumonia with septic shock.
Careful intensive care by an experienced team is crucial to
improve patients’ outcome.References
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